>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>SD 0006

SD 0006 (Synonyms: SD-006)

Catalog No.GC19325

SD 0006(SD-06)은 p38α에 대한 IC50이 110nM인 p38α MAP 키나제의 경구 활성, 선택적 ATP 경쟁적 및 강력한 디아릴 피라졸 억제제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

SD 0006 Chemical Structure

Cas No.: 271576-80-8

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$87.00
재고 있음
1mg
US$35.00
재고 있음
5mg
US$99.00
재고 있음
25mg
US$283.00
재고 있음
50mg
US$494.00
재고 있음
100mg
US$742.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SD 0006 (SD-06) is an orally active, selective, ATP-competitive and potent diaryl pyrazole inhibitor of p38α MAP kinase, with an IC50 of 110 nM for p38α[1][2].

SD 0006 clearly inhibits p38α as shown by the dose-dependent inhibition of phosphorylation of its endogenous Hsp27 substrate[1].

SD 0006 (0-30 mg/kg) may be an effective alternative to steroids and biologics for RA therapy[1].SD0006 (3.75, 7.5 and 15 mg/kg; p.o.; b.i.d.) is highly effective in attenuating SCW-induced inflammation as shown by the dose-dependent inhibition of paw swelling[1].

References:
[1]. Burnette BL, et al. SD0006: a potent, selective and orally available inhibitor of p38 kinase. Pharmacology. 2009;84(1):42-60.
[2]. Walker JK, et al. Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2634-8.

리뷰

Review for SD 0006

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SD 0006

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.